J&J-part­nered MeiraGTx aims at Bio­gen with new eye gene ther­a­py da­ta

Sev­er­al months af­ter Bio­gen tout­ed the first proof-of-con­cept da­ta from its $800 mil­lion eye gene ther­a­py, MeiraGTx and J&J are out with their own ear­ly da­ta for a ri­val treat­ment.

In a small Phase I/II tri­al for their gene ther­a­py for the de­gen­er­a­tive eye dis­ease x-linked re­tini­tis pig­men­tosa, MeiraGTx found that the 7 pa­tients in the two low­est dose co­horts saw their vi­sion im­prove on mul­ti­ple mea­sures for 6 months. The study will pro­vide the ba­sis for the New York biotech to move in­to a piv­otal Phase III for the gene ther­a­py that J&J paid $100 mil­lion to get in on last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.